Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 307Lung Neoplasms 111Adenocarcinoma of Lung 23Non-Squamous Non-Small Cell Lung Cancer 21Neoplasms 21Adenocarcinoma, Bronchiolo-Alveolar 15Brain Neoplasms 14Neoplasm Metastasis 10Squamous Cell Carcinoma of Head and Neck 5Respiratory Tract Diseases 5Carcinoma 5Breast Neoplasms 5Adenocarcinoma 5Thoracic Neoplasms 4Recurrence 4Pancreatic Neoplasms 4NSCLC 4Colorectal Neoplasms 4Colonic Neoplasms 4Salivary Gland Neoplasms 3Respiratory Tract Neoplasms 3Rectal Neoplasms 3Lung Diseases 3Esthesioneuroblastoma, Olfactory 3Carcinoma, Squamous Cell 3Carcinoma, Renal Cell 3Thymoma 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Pleural Effusion, Malignant 2

Interventions

N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 1Erlotinib Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
EGFR Mutated EGFR TKI Naive Metastatic NSCLC × Erlotinib Hydrochloride × Thoracic × Clear all
NCT02206763 2019-02-01

Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)

Sierra Oncology LLC - a GSK company

Phase 1 Terminated
11 enrolled
Thoracic

EGFR Mutated EGFR TKI Naive Metastatic NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡